Genprex Appoints John N. Bonfiglio, PhD, to Board of Directors
February 19 2019 - 8:30AM
Business Wire
Experienced Biotech Executive Brings More Than
30 Years of Pharmaceutical and Biotechnology Experience to
Genprex
Genprex, Inc. (NASDAQ: GNPX) a clinical-stage gene therapy
company developing a new approach to treating cancer based upon a
novel proprietary technology platform, announced today the
appointment of John N. Bonfiglio, PhD, to the company’s Board of
Directors. In recent years, Dr. Bonfiglio served as President and
CEO of Oragenics, Inc. and most recently as President and COO of
TapImmune, Inc., where he helped lay the groundwork for a
successful merger with Marker Therapeutics, Inc. in October 2018 by
up-listing TapImmune to Nasdaq and starting a robust clinical
program in breast and ovarian cancers. John’s more than 30 years of
experience in the pharmaceutical and biotechnology industries will
enable the Genprex Board and management team to draw on his
expertise to help guide Genprex as it continues to grow.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190219005254/en/
John Bonfiglio, PhD joins Genprex's Board
of Directors with more than 30 years of pharmaceutical and
biotechnology experience (Photo: Business Wire)
“I am honored and excited to join Genprex’s Board of Directors,”
Dr. Bonfiglio said. “I see tremendous potential for Genprex. In my
opinion, Genprex’s clinical and pre-clinical research show that its
lead drug candidate, Oncoprex™ immunogene therapy, can potentially
work synergistically in combination with targeted therapies and
immunotherapies to treat cancer patients outside of the population
normally targeted by these cancer therapies. Clinical exploration
of these areas could lead to market expansion and to new patient
populations with unmet medical needs. The market potential for
these new combination therapies is very attractive.”
Dr. Bonfiglio began his career as a scientist with Allergan,
Inc. before moving into project and business development. Over the
course of his career he has held several executive leadership
positions including President and CEO at Peregrine Pharmaceuticals,
Inc., Executive Vice President and COO of Cypress Bioscience, Inc.,
President and CEO of The Immune Response Corporation and the
President and CEO of Argos Therapeutics, Inc., among others. In
those positions, he has succeeded in raising capital, lowering burn
rates, setting corporate strategies, controlling corporate spending
and managing clinical trials. Throughout his career he has helped
raise more than $150 million in capital while helping companies
relist and up-list with national securities exchanges. Recently, he
joined the Board of Directors of GT Biopharma, Inc., adding to his
significant experience in the immuno-oncology field.
“We are excited that Dr. Bonfiglio has accepted our invitation
to join our Board of Directors,” said Rodney Varner, Genprex’s
Chief Executive Officer and Chairman. “His experience and expertise
are impressive. His background with other biotechnology companies
will provide us with extensive knowledge and resources. We believe
that Dr. Bonfiglio will make a great contribution to our future
success.”
Dr. Bonfiglio’s appointment to the Board is the latest
high-profile addition to Genprex as the company continues to grow.
In October 2018, Genprex appointed Jan Stephens, RN, as the
company’s Vice President of Clinical Operations.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company
developing potentially life-changing technologies for cancer
patients, based upon a unique proprietary technology platform,
including Genprex’s initial product candidate, Oncoprex™ immunogene
therapy for non-small cell lung cancer (NSCLC). Genprex’s platform
technologies are designed to administer cancer fighting genes by
encapsulating them into nanoscale hollow spheres called
nanovesicles, which are then administered intravenously and taken
up by tumor cells where they express proteins that are missing or
found in low quantities. Oncoprex has a multimodal mechanism of
action whereby it interrupts cell signaling pathways that cause
replication and proliferation of cancer cells, re-establishes
pathways for apoptosis, or programmed cell death, in cancer cells,
and modulates the immune response against cancer cells. Oncoprex
has also been shown to block mechanisms that create drug
resistance. Visit the company’s web site at www.genprex.com or
follow Genprex on Twitter at twitter.com/genprex, Facebook at
facebook.com/genprexinc and LinkedIn at
linkedin.com/company/genprex.
Forward-Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
the effects of Oncoprex™, and statements regarding the synergies
obtained by combining Oncoprex with targeted therapies and
immunotherapies. Risks that contribute to the uncertain nature of
the forward-looking statements include the extent of Oncoprex’s
effect on cancer, as well as the timing and success of our clinical
trials and planned clinical trials of Oncoprex and our other
potential product candidates and the timing and success of
obtaining FDA approval of Oncoprex and our other potential product
candidates. These and other risks and uncertainties are described
more fully under the caption "Risk Factors" and elsewhere in our
filings and reports with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. We
undertake no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they
were made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190219005254/en/
Genprex, Inc.(877) 774-GNPX (4679)
Investor RelationsGNPX investor relations(877) 774-GNPX
(4679) ext. #2investors@genprex.com
Media ContactGenprex Media Relations(877) 774-GNPX (4679)
ext. #3media@genprex.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024